New antibody therapy aims to stop chronic kidney transplant rejection
Disease control
Recruiting now
This trial tests a bispecific T-cell engager (BiTE) antibody in kidney transplant recipients who have chronic active antibody-mediated rejection (cAMR). The BiTE targets BCMA and CD3 to deplete harmful B cells and plasma cells that produce donor-specific antibodies. Researchers w…
Phase 4 • Sponsor: Turun Song • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC